NCT02956811View on ClinicalTrials.gov

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

March 14, 2019

Study Completion Date

April 2, 2019

Conditions
Type 2 DiabetesLeft Ventricular Hypertrophy
Interventions
DRUG

Dapagliflozin

SGLT2 inhibitor

DRUG

Placebo

Matching Placebo

Trial Locations (1)

Unknown

Ninewells Hospital, Dundee

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

NHS Tayside

OTHER_GOV

collaborator

AstraZeneca

INDUSTRY

lead

University of Dundee

OTHER